Research
Hormonal
Nordihydroguaiaretic acid (NDGA) extends median lifespan in male mice across multiple doses, but has no effect on female lifespan even when blood levels are matched to males.
NDGA extends the lifespan of male mice in a dose-dependent manner, but has no effect on female lifespan, even when blood levels are matched to those of males. This indicates a fundamental sex-specific difference in how NDGA affects longevity.
GoodQualifiesHIGH confidence
NDGA increased male median lifespan by 8–10% at three different doses... Females did not show a lifespan benefit from NDGA, even at a dose that produced blood levels similar to those in males, which did show a strong lifespan benefit.
Why this rating
Consistent male benefit across doses and sites, clear lack of female benefit despite matched blood levels.
Source
Acarbose, 17‐α‐estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males
David E. Harrison et al. · Aging Cell · 2013
DOI 10.1111/acel.12170
rctCited 461×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Acarbose extends median lifespan in male mice significantly more than in female mice, despite reducing body weight more in females.Good
- 17-alpha-estradiol extends median lifespan in male mice, with effects varying significantly by testing site, but has no effect on female lifespan.Moderate
- Methylene blue does not significantly extend median lifespan in male or female mice, but significantly increases maximum lifespan (90th percentile) in females.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →